Contrave Rxs Jump In Q1, But TV Commercial Runs Afoul Of FDA
Orexigen touts 39% growth in US sales of its obesity drug; agency objects to advertisement for excluding risk information.
You may also be interested in...
Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.
Beware the Ides of March, especially if you're an investor in the obesity drug market. Orexigen added further evidence that the market is crumbling as it hitched its wagon to a partner that is even worse off.
Medical and advocacy groups claim FDA is requiring women to fill prescriptions for Mifeprex in person while waiving REMS requirement for in-person visits for other drugs.